2014;37(2):e22-23
Public batch ID: 5A1MQ-B001-5MG Current batch Batch 5A1MQ-B001 Janoshik Analytical batch-specific analytical report Proves identity Proves purity Checks amount Sterility not tested unless listed Research & library Research review Scientific background, literature, and compound context COA library Browse current and supporting batch documentation Scope limit: COAs document analytical testing for research materials
As of April 22, 2026, it was removed from FDA Category 2, but the FDA's Pharmacy Compounding Advisory Committee will not consider it for the 503A bulks list until the July 23, 2026 meeting
[2] The decline of GH results in reduced production of insulin-like growth factor (IGF-1), which typically works in tandem to manage and modulate our fat, protein, and glucose metabolism
Many people turn to NAD+ when they want better focus, more endurance, and improved cognitive abilities without the need for stimulants